鉴定和验证SLC9A2作为结直肠癌潜在瘤抑制剂:将生物信息学分析与实验确认相结合

Yan-Min Liu1, Tie-Cheng Yang2,3,4, Xiao-Chang Fang2,3,4

  • 1Department of Gastroenterology, the Central Hospital of Wuhan, Key Laboratory for Molecular Diagnosis of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430014, China.

PubMed
概括

这项研究确定SLC9A2是结直肠癌 (CRC) 的瘤抑制剂. 过度表达SLC9A2抑制CRC细胞生长和转移,表明其作为诊断和治疗点的潜力.